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Objective: To evaluate healing of surgically created large osteochondral defects in a weight-bearing
femoral condyle in response to delayed percutaneous direct injection of adenoviral (Ad) vectors con-
taining coding regions for either human bone morphogenetic proteins 2 (BMP-2) or -6.
Methods: Four 13 mm diameter and 7 mm depth circular osteochondral defects were drilled, 1/femoral
condyle (n¼ 20 defects in ﬁve ponies). At 2 weeks, Ad-BMP-2, Ad-BMP-6, Ad-green ﬂuorescent protein
(GFP), or saline was percutaneously injected into the central drill hole of the defect. Quantitative
magnetic resonance imaging (qMRI) and computed tomography (CT) were serially performed at 12, 24,
and 52 weeks. At 12 (one pony) or 52 weeks, histomorphometry and microtomographic analyses were
performed to assess subchondral bone and cartilage repair tissue quality.
Results: Direct delivery of Ad-BMP-6 demonstrated delayed gadolinium-enhanced MRI of cartilage
(dGEMRIC) and histologic evidence of greater Glycosaminoglycan (GAG) content in repair tissue at 12
weeks, while Ad-BMP-2 had greater non-mineral cartilage at the surface at 52 weeks (p< 0.04). Ad-BMP-
2 demonstrated greater CT subchondral bone mineral density (BMD) by 12 weeks and both Ad-BMP-2
and -6 had greater subchondral BMD at 52 weeks (p< 0.05). Despite earlier (Ad-BMP-6) and more
persistent (Ad-BMP-2) chondral tissue and greater subchondral bone density (Ad-BMP-2 and -6), the
tissue within the large weight-bearing defects at 52 weeks was suboptimal in all groups due to poor
quality repair cartilage, central ﬁbrocartilage retention, and central bone cavitation. Delivery of either
BMP by this method had greater frequency of subchondral bone cystic formation (p< 0.05).
Conclusions: Delivery of Ad-BMP-2 or Ad-BMP-6 via direct injection supported cartilage and subchondral
bone regeneration but was insufﬁcient to provide long-term quality osteochondral repair.
Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
Weight-bearing full thickness articular cartilage lesions in the
femoral condyle occur frequently, are difﬁcult to heal, negatively
affect the surrounding cartilage and, often lead to degenerative
arthritis and pain1. Currently, these lesions are managed by several
surgical and cell-based approaches such as subchondral drilling,
abrasion, micro-fracture2, osteochondral autograft transfer (OAT)3,A.L. Bertone, The Ohio State
ratory, College of Veterinary
n Tharp Street, Columbus, OH
ertone).
r Ltd on behalf of Osteoarthritis Reautologous chondrocyte implantation (ACI)4, matrix-induced
autologous chondrocyte implantation (MACI)5, and juvenile allo-
geneic chondrocyte implantation6. The long-term regeneration of
hyaline cartilage achieved with these methods, however, is less
than clinically acceptable in large weight-bearing osteochondral
defects7e9. Current pre-clinical experimental procedures evalu-
ating use of genes and cells, such as IGF and BMP-7, and cells, such
as chondrocytes and stem cells, have shown promise to enhance
cartilage healing10,11, but are limited in scope and have not been
followed serially in a live animal model.
Due to the fact that there is currently no regimen, either phar-
macological or surgical, that is capable of restoring damaged
cartilage to its normal phenotype, there is a good incentive for
pursuing alternatives, such as gene transfer. Among the list ofsearch Society International.
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factors of the transforming growth factor (TGF)-ß superfamily,
including several bone morphogenetic proteins (BMPs)12,13. There
is evidence that BMP-2 and BMP-6 can be chondrogenic both
in vitro and in vivo in animal models14. It is well known that both
BMP-2 and BMP-6 are potently osteogenic and can enhance and
accelerate bone regeneration in vivo15e18.
Our hypothesis was that BMPs may provide improved
subchondral bone formation in healing large full-thickness weight-
bearing articular cartilage defects, as well as support chondro-
genesis and restoration of the articular cartilage surface. We
selected the use of several quantitative serial imaging modalities to
assess bone and cartilage restoration over time and to evaluate
intra-lesional delivery of BMP-2 and BMP-6 gene therapy.Materials and methods
Study design
Procedures performed for this study were reviewed and
approved by the Institutional Animal Care and Use Committee at
The Ohio State University. Five healthy, skeletally mature ponies
(weighting 121e161 kg) underwent general anesthesia induced by
xylazine (Rompun; Bayer, Pittsburgh, PA, USA; intravenously (i.v.),
1.1 mg kg), ketamine (Ketaset; Fort Dodge Animal Health, Overland
Park, KS, USA; i.v., 2.2 mg kg) and diazepam (Valium; Roche, Mad-
ison,WI, USA; i.v., 0.11 mg kg) andmaintained by Isoﬂurane (IsoFlo;
Abbott, Parsippany, NJ, USA; infusion, 2e5%). The ponies were
positioned in dorsal recumbency and via arthrotomy, four 13 mm
diameter and 7 mm depth circular osteochondral defects were
drilled, 1/femoral condyle (n¼ 20). Additionally, a 2.5 mm in
diameter and 10 mm depth hole was drilled within each lesion
(Fig. 1). Two weeks after the surgery, adenoviral (Ad) containing
green ﬂuorescent protein (GFP), Ad-BMP2, and Ad-BMP6 vectors
were diluted into a 500 ml total volume with GBSS containing
4109 infectious units (IFU) (Ad-BMP-2) and 2.4109 (Ad-BMP-
6). Under general anesthesia, each pony had the osteochondral
femoral lesions treated with percutaneous direct ﬂuoroscopic
guided injections of Ad-BMP2 (n¼ 5), Ad-BMP6 (n¼ 5), Ad-GFP
(n¼ 5; vector control) or Gey’s balanced salt solution (n¼ 5; GBSS
control e SigmaeAldrich, St Louis, MO, USA). The four defects inFig. 1. Images of osteochondral femoral defects in the pony model. Initially at surgery (A) and
ROIs for lesion (red) and subchondral bone (blue) (C), micro-CT resolution of healing lesion
histochemistry of Ad-GFP (F) and Ad-BMP6 (G). Positive safranin-O staining in the defect on
T1Gd relaxation time (GAG content) in the BMP-6 treated lesion.each pony were assigned in a block design to rotate the treatments.
Ponies were conﬁned to a boxstall for 26 weeks, then paddock
turnout for 26 weeks.
At 12 or 52 weeks, after undergoing quantitative magnetic
resonance imaging (qMRI), the ponies were euthanized. Efﬁcacy
was assessed by qMRI, clinical CT, ex vivo mCT, histology and gene
expression analysis. Evidence of systemic biodistribution of vector
was assessed by physical examination and quantitative polymerase
chain reaction (PCR) for the cytomegalovirus (CMV) promoter
region of the Ad in multiple organ tissues.
Ad vector production and treatments
Recombinant, replication-deﬁcient, serotype-5 Ad vectors con-
taining either a 1547 base-pair open reading frame segment of
human BMP-2 (Ad-BMP-2), BMP-6 (Ad-BMP-6) or GFP (Ad-GFP)
under the control of the CMV promoter were generated as previ-
ously reported14,16e18. The expression of transgenes was veriﬁed in
cell culture14. The IFU/ml of Ad-BMP-2, Ad-BMP-6 and Ad-GFPwere
calculated according to manufacturer’s instructions using
a commercially available kit (Clontech Laboratories, Inc., Mountain
View, CA, USA)19.
qMRI
At 12, 24, and 52 weeks after the osteochondral lesions (OLs)
were treated, under general anesthesia, in a 3 Tesla MRI (Achieva,
Philips, Cleveland, Ohio, USA), qMRI was performed using a trans-
mit quadrature body coil in combination with a four-channel array
of 10 cm loop coils/knee.
Dynamic contrast enhanced-magnetic resonance imaging
(DCE-MRI)
DCE-MRI was performed by administering a bolus injection of
double dose (0.2 mmol/kg) post-gadopentate dimeglumine
(Gd-DTPA; Magnevist, Wayne, NJ, USA) while acquiring a three-
dimensional (3D) T1 weighted turbo ﬁeld echo (T1-TFE) sequence
(RepetitionTime (TR)/EchoTime (TE)¼ 3.15/1.60 ms;ﬂip angle¼ 12⁰;
TFE factor¼ 50; Field of View (FOV)¼ 64180180 mm3;
matrix¼ 32120120; slice thickness¼ 4 mm; 30 dynamic scans,
15.14 s/scan). Dynamic parameters were calculated by ﬁtting toat 12 weeks in sagittal section in 3D T2 weighted MRI (B), live pony clinical CT showing
(D), gross photograph showing less than acceptable cartilage repair (E) and Safranin-O
histology of the Ad-BMP-6 treated defect supported the MRI ﬁndings in Fig. 2 of greater
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sampled from the popliteal artery using LevenbergeMarquardt20,21.
Delayed gadolinium-enhanced MRI of cartilage (dGEMRIC)
A sagittal slice through each defect was imaged via a multi-
inversion recovery turbo spin echo (IReTSE) sequence (TR/
TE¼ 3740/28 ms; TSE factor¼ 10; FOV¼ 165165mm2; matrix¼
332 328; slice thickness¼ 3 mm). Six acquisitions were taken of
each slicewith varied inversion times (0, 60,150, 350,1100,1680ms).
Post-Gd-DTPA imaging was taken after 30 min of passive exercise
following injection. This protocol was adapted from human clinical
patients22. T1 values were calculated by performing Lev-
enbergeMarquardt least-squares ﬁt.
T2 mapping
A multi-echo TSE sequence (TR/TE¼ 3000/10, 20, 30, 40, 50,
60,70,80 ms; FOV¼ 165165 mm2; matrix¼ 164165; slice
thickness¼ 3 mm) was performed on each defect. T2 values were
calculated via linear least-squares ﬁt23. All calculations were
performed using in-house software written in the IDL environ-
ment (Interactive Data Language, ITT Visual Information Systems,
Boulder, CO). Regions of interest (ROIs) outlining the OL and
adjacent non-injured cartilage located 1 cm distant from the
lesion in a sagittal cross section were manually traced by two
authors blinded to treatments (MIM, DJC). Outcome measure-
ments included: T1Gd (after gadopentate dimeglumine adminis-
tration) for dGEMRIC, T2 relaxation time for T2 mapping and
Amplitude (relative intensity of contrast enhancement after
injection) for DCE-MRI.
Live pony computed tomography (CT)
CT was performed at 12 and 24 weeks after treatment under
general anesthesia with a Lightspeed 3 (GE Healthcare, Wiscon-
sin, USA). The images were acquired in bone algorithm and
reconstructed in detail (soft tissue) algorithm (170 mA, 140 kVp,
40 cm FOV) using a transverse scan; 0.625 mm contiguous images
were scanned. The image was comprised from tissue just proximal
to the patella to 2 cm distal to the tibial plateau. The ponies were
positioned in left lateral recumbency with pelvic limbs in extension
(feet ﬁrst through gantry). A dipotassium phosphate phantom was
placed on top of right stiﬂe. Data was registered and analyzed
within the Inveon Research workplace (Siemens, Knoxville, TN,
USA). ROI’s were traced for the OLs and surrounding subchondral
bone without knowledge of the treatment groups (MIM, MC).
Outcomes quantiﬁed included: bone mineral density (BMD) in OLs
and BMD in surrounding subchondral bone.
Quantitative micro-computed tomography (qmCT)
Fifty-two weeks after vector injection, and following MRI,
ponies were sedated with xylazine and euthanized by lethal
intravenous overdose of pentobarbital (Beuthanasia; i.v., 2.2 mg/
kg). Immediately after the euthanasia, tissues were harvested and
the femoral condyles were photographed and dissected. qmCT
(Inveon, Siemens, Knoxville, TN, USA) was analyzed using a crop-
ped Siemens format, registered to TIFF format in RATOC (Japan) to
provide correct alignment of the lesions. Data was converted to
a RAW volume and imported to Inveon Research Workplace as
DICOM images to generate the ROIs. The threshold level for carti-
lage was established at a RAW value of 32,000 units which corre-
sponds to 874 mg/cc absolute density and 277 mg of Ca/cc
collagen. Outcome measurements included lesion area (mm2) and
BMD for the lesion, drill and adjacent subchondral bone ROIs
(Fig. 5).Gross photograph evaluation
Standardized digitized color photographs were taken for gross
assessment of the surface. The repair tissue surface was semi-
quantitatively scored by two authors (MIM, ALB) blinded to treat-
ment from 0 (not present) to 4 (present in >75% of the area) for
perimeter gap, surface irregularity and cartilage recess11. The
location and presence of central cavitations were noted and
expressed as a frequency by group.
Histological evaluation
Sagittal cross-sectioned blocks of femoral condyle osteochon-
dral defects were ﬁxed with 10% neutral-buffered formalin and
decalciﬁed in formic/hydrochloric acid (8% solution of each).
Specimens were parafﬁn-embedded, sectioned at 5 mm, and
stained with H&E, Toluidine Blue and Safranin-O Fast Green.
Sections were examined by three investigators blinded to lesion
treatments (SEW, ALB, MIM). Outcome parameters included
chondrocyte cloning, hypocellularity, cartilage repair thickness,
surface irregularity and safranin-O staining11(Fig. 5; Table I).
Gene expression analyses via reverse transcription PCR (RT-PCR)
Two-step RT-PCR was performed using RNA extracted from
intra-lesional tissue, surrounding cartilage, synovial membrane,
and liver. Total RNA was extracted by TRIzol (Invitrogen Life Tech-
nologies, Carlsbad, CA, USA) from fresh homogenized tissues using
established protocol16 and cDNA was constructed using TaqMan
Reverse Transcription Reagents (Applied Biosystems, Foster City,
CA, USA). Primers for the hbmp2 (forward: AAAACGTCAAGC
CAAACACAAA; reverse: GTCACTGAAGTCCACGTACAAAGG), hbmp6
(forward: CAACAGAGTCGTAATCGCTCTAC: reverse: TTAGTGG
CATCCACAAGCTCT) and GFP gene (forward: CATGATATAGACGT
TGTGGCTGTTG-3; reverse: AAGCTGACCCTGAAGTTCATCTGC) were
used in Ad-GFP, Ad-BMP-6, and Ad-BMP-2 treated tissue to detect
presence of active transcription.
Biolocalization of Ad vectors
Genomic DNA was extracted from liver (n¼ 4), synovium
(n¼ 16), and cartilage surrounding the lesion at 1 year (n¼ 16),
using the QIAamp Mini Kit (Qiagen, Valencia, CA, USA). PCR was
performed using primers (forward: CTGGCTGACCGCCCAACGAC;
reverse: CACCGTACACGCCTACCGCC) that amplify CMV sequences.
Statistical analysis
Repeated-measure analysis of variance (ANOVA) (SAS Institute
Inc., Cary, NC, USA) evaluated the effects of Ad-BMP gene therapy
using Proc Mixed models for continuous dependent variables (i.e.,
MRI, micro-CT) and Genmod models for categorical dependent
variables (i.e., histologic data). The independent variables
included treatments, time points, limbs, and horses. Of these,
repeated variables included treatments and time points, and were
considered to be nested within horses. The ﬁxed effects analysis
was performed, whereas horse was treated as a random variable
in the model. The distribution of data was assessed by the use of
a subset of normality tests and was fulﬁlled. The post-test
multiple comparisons were made between the treatment
groups, among time points, or between the lesion and control
sites (i.e., MRI). The frequency outcomes in histology (i.e., cystic
formation, cartilage contiguity) were compared between the Ad-
BMP-2/6 and non-Ad-BMP-2/6 groups using Chi-square test. A
sufﬁcient sample size of four was computed using published gene/
Fig. 2. Representative quantitative MRI maps of sagittal sections through the osteochondral defect, showing a lesion treated with Ad-BMP-6 across time using three different
quantitative techniques (T2 mapping, dGEMRIC and DCE-MRI). (A) 3D T2-weighted image shows the anatomy and subchondral bone changes (edema) in the distal femoral
condyles, and also displays the traced lesion and adjacent cartilage ROIs. T2 mapping showed a greater T2 relaxation time in the treated lesion than the adjacent cartilage at all time
points (p< 0.02). DGEMRIC, T1Gd is signiﬁcantly lower in the treated OLs than the adjacent cartilage (p< 0.01). For color map DCE-MRI, Amplitude was greater in the lesion at 12
weeks than either 24 (p< 0.006) or 52 (p< 0.001) weeks. Amplitude greater in the lesion at 12 weeks (p< 0.0001) and 24 weeks (p< 0.005) than adjacent cartilage. By 52 weeks,
Amplitude in the lesion was almost negligible and was similar to the adjacent cartilage. The adjacent cartilage values were low, but were greater at 12 weeks (p< 0.004) and 24
weeks (p< 0.02) than at 52 weeks. The OL decreased in size over time, and subchondral bone changes were evident from 12 weeks. (B and C) At 12 weeks, dGEMRIC showed greater
T1Gd relaxation time (GAG content) in the BMP-6 treated lesion than GBSS (p< 0.017). (C) Mean T2 relaxation time, T1Gd relaxation time and Amplitude from the OL and the
adjacent cartilage at 12, 24, and 52 weeks. Asterisks (*) showed signiﬁcant difference between Ad-BMP-6 and GBSS. Different letter superscripts among time points are statistically
different (p< 0.05) regardless of treatment group. #Represents a signiﬁcant difference between lesion and adjacent cartilage (p< 0.05) regardless of treatment group.
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with a signiﬁcance level of 0.05 and power of 0.8 (www.
dssresearch.com)16,24. Only statistically signiﬁcant or positive
results were reported in text.Results
Ponies were not permitted to be mobile for the ﬁrst week and
stood quietly. Mobility limitations were not noted in stalls or
Fig. 3. BMD mean standard error of the mean (S.E.M.) in a live clinical CT at 12 and 24
weeks. Ad-BMP-2 treated osteochondral defects had small but statistically greater
BMD than GBSS at 12 weeks (#; p< 0.038) in surrounding subchondral bone. BMD at
24 weeks (b) was greater than 12 weeks (a) regardless of treatment in both the lesion
(p< 0.007) and in subchondral bone (p< 0.002).
Fig. 4. Mean S.E.M. non-mineral area (mm2) in OL and Mean S.E.M. BMD (mg/cc)
related to micro-CT ﬁndings. Each bar represents the indicated treatment. BMD in the
drill hole was statistically greater in the Ad-BMP-6 treated bone (b; p< 0.017) and non-
mineral area was statistically greater in the Ad-BMP-2 treated lesion (b; p< 0.046).
Different letter superscripts are different among treatments (p< 0.05). (NS¼ no
signiﬁcant ﬁndings).
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weeks due to unrelated accidental mortality and remaining ponies
at 12, 24, and 52 weeks.
MRI
DCE-MRI
Amplitude in the lesion was signiﬁcantly greater at 12 weeks
than 24 (p< 0.006) and 52 (p< 0.0013) weeks, and was negligible
and similar to adjacent cartilage by 52 weeks regardless of treat-
ment. Amplitude of adjacent un-injured cartilage was low, but
statistically greater at 12 weeks (p< 0.0043) and 24 weeks (<0.02)
than 52 weeks (Fig. 2).
dGEMRIC
Lesions treated with Ad-BMP-6 had a greater T1Gd relaxation
time (GAG content) at 12 weeks (p< 0.017) than GBSS treatment.
The adjacent non-injured cartilage had a signiﬁcantly lower T1Gd
value than lesion repair tissue for all time points, 12 (p< 0.000016),
24 (p< 0.0029) and 52 weeks (p< 0.01). At 52 weeks T1Gd values
(GAG content) were lower in both the lesion and the adjacent
cartilage than at 24 weeks (p< 0.04) (Fig. 2).
T2 mapping
T2 relaxation time was signiﬁcantly greater in the lesion than in
adjacent cartilage (p< 0.01) without differences among groups or
time (Fig. 2).Live pony CT
The subchondral bone surrounding the lesions treated with Ad-
BMP-2 at 12 weeks had greater BMD than the GBSS group
(p¼ 0.038). Additionally, the lesion, as well as the surrounding
subchondral bone, had an increase in BMD from 12 to 24 weeks
(p< 0.006) (Fig. 3).
qmCT
The non-mineral ROI (mm2) for the BMP-2 group was signiﬁ-
cantly greater than the GBSS group (p< 0.046)(Figs. 5, 6). The BMD
within the drill ROI was signiﬁcantly greater in the BMP-6 treated
lesion than the GBSS group (p< 0.017) (Figs. 4, 5).
Gross photograph evaluation
Perimeter gap scorewas lower in lesions treatedwith Ad-BMP-2
than control groups (GBSS and Ad-GFP) (p< 0.037). BMP-treated
lesions had a greater frequency of central cavitation formation
than non-BMP-treated lesions (Fig. 5; Table I) (p< 0.05).
Histological evaluation
Histomorphometry at 52 weeks showed greater chondrocyte
cloning and chondrone formation at the integration of the lesion
and the adjacent un-injured cartilage in the lesions treated with
Ad-BMP-2 and Ad-BMP-6 (p< 0.04) (Fig. 5). The frequency of
subchondral bone cystic formation was greater in the lesions
treated with BMPs (BMP-2 plus BMP-6; p< 0.05) than in lesions
treated without BMPs (GBSS plus Ad-GFP). Irregular surface score
was lower for Ad-BMP6 treated group than GBSS group (p< 0.034)
(Fig. 5; Table I)
Histology at 12 weeks demonstrated positive safranin-O stain-
ing within the surface repair tissue of the Ad-BMP-6 group and not
present in other groups (Fig. 1).
Gene expression analysis
RT-PCR at 12 weeks detected gene expression of BMP-2 and GFP
within the lesions and GFP in adjacent cartilage. RT-PCR at 52
weeks detected gene expression of GFP in one sample of adjacent
cartilage.
Biolocalization of Ad vectors
DNA from the CMV promoter portion of the Ad vector was
detected in surrounding cartilage at 52 weeks in BMP-2, BMP-6 and
Fig. 5. Post-mortem representativemicro-CTand histomorphometry for OL treatedwith GBSS, Ad-BMP-2 and Ad-BMP-6 at 52weeks. Themicro-CTshows greater area of non-mineral
tissue (mm2) (as in Fig. 4) for the Ad-BMP-2 treated lesions (p< 0.046) (B) as well as changes in the subchondral bone, interpreted and corroborated by histology as a cyst (D). 3D
images of the OL showing subchondral bone are represented as insets in the right corners. Gross photographs (EeH) demonstrated that lesions treatedwith BMPs had lower perimeter
gap (arrow), better integration (arrow), and less irregular surface (*) (F, G) than GBSS, which presented greater frequency of central cavitation formation (E; arrow). Safranin-O staining
at 10 reﬂected a greater chondrocyte cloning (arrows) where the lesion integrated with the adjacent un-injured cartilage (zone 1) in lesions treated with BMP-2 and BMP-6 (M, N).
Numbers in ﬁgure L represent the zones used to evaluate histomorphometry (see Table I).
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in other tissues, including synovial membrane and liver.
Discussion
Single, delayed injection of adenovirus encoding BMP-2 or BMP-
6 genes was beneﬁcial in the short term to accelerate GAG con-
taining repair cartilage, and/or subchondral bone density, in large,
weight bearing surgically created OLs. Vector injection 2 weeks
after surgery into solid granulation tissue has been shown to be
advantageous to contain the Ad-BMP in an osteotomy healing
site24,25. Presumably, transcribed and secreted BMP functions in the
local region and targets host cells16e18. To our knowledge, our study
is the ﬁrst to show this effect in osteochondral healing sites. Our
central drill hole provided a site within the lesion for localized
delivery of gene transfer vectors to provide sustained and
concentrated protein synthesis at the site of the created lesion.
Limited spill over of vector to adjacent cartilage was expected and
conﬁrmed. Our study detected the CMV promoter portion of the Advector at 52 weeks in adjacent cartilage documenting the injection
of the vector near the OL and persistence of adjacent cartilage cells
for over 1 year. It has been demonstrated that Ad vectors success-
fully transduced chondrocytes within the surface of canine and
guinea pig cartilage explants and, in vivo, Ad-GFP expression per-
sisted for 12 weeks in ﬁve of 24 specimens19, although is known to
have transient expression19. We did not ﬁnd CMV promoter in
synovial membrane at 52 weeks supporting our interpretation that
the vector was retained at or near the lesion.
Our study demonstrated greater T1Gd values in the Ad-BMP-6
group than in the GBSS control (p< 0.05) early in lesion healing
(12 weeks). This imaging ﬁnding was conﬁrmed by histology.
Because GAG is composed of abundant carboxyl and sulfate groups,
it is negatively charged within the cartilage matrix. Anionic gado-
pentate dimeglumine (Magnevist, Wayne, NJ, USA), given a sufﬁ-
cient time after its injection to penetrate the cartilage, will
distribute inversely to the concentration of negatively charged
cartilaginous GAG26. The protocol for administration of Gd in the
ponies was similar as used in human clinical patients with
Table I
Histomorphometry and gross photograph osteochondral parameters
(A) Histomorphometry
Parameter Treatment Zone 1 Zone 2 Zone 3 Zone 4 Zone 5 Zone 6
Chondrocyte cloning score [median (range)]
GBSS 0 (0e1) 0 (0e2) 0 (0) 0 (0) 0 (0) 0 (0)
Ad-GFP 0.5 (0.5e1.5) 1.5 (0e2) 0 (0) 0 (0e0.5) 0 (0) 0 (0)
Ad-BMP2 2.0 (1e3.5)* 0.5 (0e0.5) 0 (0) 0 (0e0.5) 0 (0) 0 (0)
Ad-BMP6 1.0 (1e3)* 0.3 (0e2) 0 (0) 0 (0e2) 0 (0) 0 (0)
Hypocellularity score [median (range)]
GBSS 3.0 (1.5e4) 0 (0e2) 0 (0e0.5) 0 (0e0.5) 0 (0) 0 (0)
Ad-GFP 2.0 (1.5e3.5) 0 (0) 0 (0e0.5) 0 (0e1) 0 (0) 0 (0)
Ad-BMP2 3.5 (2e4) 0 (0e1) 0.3 (0e1) 0.5 (0e1) 0 (0) 0 (0)
Ad-BMP6 3.3 (3e3.5) 0.8 (0e1.5) 0 (0e0.5) 0 (0) 0 (0) 0 (0)
Thickness repair (%) [mean S.E.M.]
GBSS 58.3 9.3 100.0 19.0 51.3 19.6 0 0 0 0 100.0 0
Ad-GFP 71.7 15.1 81.0 8.3 78.3 12.8 0 0 0 0 100.0 0
Ad-BMP2 67.5 10.1 114.5 28.9 80.8 10.6 0 0 0 0 100.0 0
Ad-BMP6 63.8 5.2 103.3 15.0 80.0 31.0 0 0 0 0 100.0 0
Surface irregularity (index) [median (range)]
GBSS 0.1 (0e0.3) 0.8 (0e1.4) 0 (0) N/A N/A 0 (0)
Ad-GFP 0 (0e0.3) 0 (0e1.1) 0 (0e0.2) N/A N/A 0 (0)
Ad-BMP2 0.3 (0e9) 0.9 (0e2.8) 0.3 (0e2) N/A N/A 0 (0)
Ad-BMP6 1.6 (0.3e3.3) 0.5 (0e1.5) 0.2 (0e0.5) N/A N/A 0 (0)
Safranin-O staining score [median (range)]
GBSS 0.6 (0e1.6) 1.2 (0.6e2.2) 1.2 (0.3e1.6) 1.7 (0.5e2.6) N/A 3.5 (2e4)
Ad-GFP 1.5 (0.2e3) 2.4 (0.2e3) 0.6 (0.2e1.4) 1.5 (0.4e3.3) N/A 4.0 (3.5e4)
Ad-BMP2 0.6 (0.3e3) 1.0 (0.9e2.2) 1.2 (0.1e1.8) 2.6 (0.9e2.8) 0.7 (0.2e1.2) 2.3 (0.8e2.9)
Ad-BMP6 0.5 (0.2e1.5) 2.2 (0.9e2.7) 1.0 (0e2.1) 0.3 (0e3.4) 0.1 (0.1) 3.9 (1.5e4)
(B) Gross photograph parameters
Parameter GBSS Ad-GFP Ad-BMP2 Ad-BMP6
Central cavitation frequency 1/4 0/4 1/4 2/4
Perimeter gap score [median (range)] 4 (3e4) 2 (2) 1 (0e1)* 2 (1e4)
Irregular surface score [median (range)] 3 (3e4) 2.5 (1e4) 1.5 (1e4) 1.5 (0e3)*
Estimate of recessed score [median (range)] 1.5 (1e2) 1 (1e4) 0.5 (0e2) 1.5 (0e3)
See Fig. 5 (L) for zone number reference.
* Differs from GBSS (p< 0.04).
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chondrogenesis. It has been shown that over-expression of BMP-2
by Ad vector gave rise to increased proteoglycan synthesis by
more than 300% compared with normal turnover proteoglycan
synthesis27. The limitations of small size and site morbidity of using
biopsy specimens for GAG assessment can be avoided by use of MRI
which can provide information on the whole cartilage surface. In
addition, MRI is noninvasive and serial scans can be performed,Fig. 6. Detection of active transcription at 12 weeks and adenovirus DNA at 52 weeks.
Transcription of GFP was detected via RT-PCR from RNA collected from adjacent
cartilage at 12 weeks. The CMV portion of adenovirus vectors were detected in DNA
samples taken from surrounding cartilage at 52 weeks in Ad- BMP-2, Ad-BMP-6, and
Ad-GFP treated specimens.allowing longitudinal monitoring at different time points. MR
images have been shown to correlate with biochemical composi-
tion in other tissues, in cartilage in vivo, and in engineered
cartilage28,29.
Quantitative CTconﬁrmed greater BMD in the subchondral bone
of BMP-6 and BMP-2 lesions. Additionally, at 52 weeks, BMP-2
lesions had a greater non-mineral lesion area, indicating, and
supported by histology, a greater amount of cartilage repair tissue
centrally at the surface of the lesion (Fig. 5). In the literature, BMP-2
is proposed as a stimulant for cartilage regeneration. BMP-2 is able
to stimulate proteoglycan synthesis in murine cartilage and
enhances collagen type II expression in chondrocytes seeded in
alginate30, 31. Also in rats and humans, BMP-2 is able to stimulate
the chondrogenic phenotype on the mRNA level and to stimulate
cartilage extracellular matrix proteoglycan production32,33.
Furthermore, BMP-2 boosts matrix turnover in intact and
interleukin-damaged cartilage, contributing to the intrinsic repair
capacity of damaged cartilage27.
Our imaging data supported that both BMP-2 and -6 may
enhance chondrogenesis as well as osteogenesis when injected
directly into the defect using an Ad vector. Concomitantly, both
BMP-2 and BMP-6 had greater integration of the repair tissue with
surrounding cartilage both grossly and histologically. (Fig. 5)
Interestingly, a dramatic and signiﬁcantly greater density of chon-
drocyte cloning occurred in this repair cartilage tissue/adjacent
cartilage interface suggesting a trophic effect of the BMPs and
resultant chondrocyte proliferation (Fig. 5). The result was a solid
cartilage tissue within the lesion/adjacent cartilage interface likely
M.I. Menendez et al. / Osteoarthritis and Cartilage 19 (2011) 1066e1075 1073translating to a more stable weight-bearing osteochondral repair.
However, regardless of these composite ﬁndings that Ad-BMP-2
and/or Ad-BMP-6 supported cartilage repair and denser sub-
chondral bone in healing osteochondral defects, this did not
translate into effective, clinically acceptable healing of the defect.
Long-term assessment of Ad-BMP-2/6 delivery by this method
resulted in greater central cavitation of the repair tissue and sub-
chondral bone cystic formation. BMPs may promote cystic forma-
tion due to acceleration of bone remodeling, which includes bone
absorption prior to bone deposition34. Bone resorption on aweight-
bearing surface area may predispose to cavitation due to pressure
on loading. Further investigation of alternate strategies to deliver
BMPs to osteochondral defects, such as use of other vectors, cell
delivery or recombinant protein delivery in scaffolds, with or
without cells, might be warranted. It is conceivable, however, that
this effect may be due to the BMPs and may persist regardless of
method of delivery.
In MRI, as expected, the lesion, compared to adjacent articular
cartilage, had lower T1Gd values, thus, lower GAG content than the
adjacent un-injured cartilage. Interestingly, at 52 weeks the un-
injured adjacent cartilage was signiﬁcantly lower than 12 and 24
weeks suggesting loss of GAG throughout the cartilage in knees
with chronic poor healing defects. This may represent early signs of
arthritic changes and OA degeneration in the knee as awhole. Other
considerations for this effect include the observation by Van der
Kraan et al. that elevated BMP levels in damaged cartilage can on
one side contribute to tissue repair by boosting matrix synthesis
but on the other side stimulate cartilage degeneration by altering
chondrocyte behavior and stimulating MMP-13 expression. These
effects could be protective for articular cartilage but can also have
a harmful role35.
Currently used cartilage repair techniques, both experimental
and clinical, are still unable to generate a repair tissue that is
comparable to the native cartilage tissue quality and stability,
particularly in large defects on the weight-bearing surface of the
knee. Although short-term success in generating hyaline cartilage
repair tissue after 6 weeks in vivo has been demonstrated, long-
term in vivo analyses indicate only unsatisfactory results36e38.
Hidaka et al. conducted a cartilage repair study in horses using
chondrocytes transduced with Ad-BMP-7. Compared to defects
receiving unmodiﬁed cells, healing was accelerated at 4 week.
However, by 8 months this difference had disappeared and few
donor cells could be detected in the repair tissue37. Contrarily, Cook
et al. showed that a collagen/BMP-7 construct was able to induce
a hyaline-like repair of full thickness defects in a canine osteo-
chondral model and to maintain repair over the course of 1 year. In
addition, acceleration of subchondral bone ﬁlling was noted in
collagen/BMP-7 treated defects at early-time periods, which may
have aided repair11. In cell delivery of BMPs, donor cell survival may
be an issue for cartilage repair, unlike bone where cell turnover is
part of the natural physiology of the tissue39. In collagen constructs,
control groups are collagen alone and comparison to untreated
defects was not made.
Healing of full-thickness large osteochondral defects on the
femoral condyle of larger species, including human, are notoriously
difﬁcult to obtain a long-term clinically effective repair tissue. Our
study demonstrated some evidence for BMP-2 or -6 to provide
potential beneﬁt to cartilage and subchondral bone healing, but the
method of gene delivery, as well as location and size of the defects,
or possible undetected leakage of vector among compartments,
may have contributed to the lack effective healing. For a successful
gene therapy approach for cartilage repair, the mode of delivery,
level and duration of transgene expression, as well as the type and
dosage of vectors used have to be well considered36,38 Alternatives
such as use of adeno-associated viral vectors, use of cells orscaffolds as delivery vehicles, and various targeting strategies may
enhance the biologic response to BMPs in this location. The
combination of BMP-2/-6 may be synergistic although synergy was
not noted in osteogenic differentiation of stem cells in vitro using
BMP2/739.
Our study is the ﬁrst to report the use of ponies as a more
relevant equine model to successfully evaluate serial healing
osteochondral defects in living subjects. Using serial, non-invasive
in vivo imaging modalities (MRI and CT) offer the advantage to
follow osteochondral regeneration within individual subjects
across time, avoiding invasive techniques such as biopsies. The
equine cartilage defect repair model is particularly relevant to
cartilage healing in humans. The thickness of equine cartilage,
including the thickness of the calciﬁed cartilage and the sub-
chondral bone plate, is closer to humans than any other animal
used for experimental studies of cartilage repair40. The biochem-
ical, biomechanical and histological characteristics of equine repair
and cartilage tissue are particularly well-deﬁned41e46. The limita-
tions of the traditional equine model include body weight and size
(w450 kg), which limit imaging modalities to disarticulated knees
and can produce excessive load stress on weight-bearing joint
surfaces. The pony model is an equine alternative that closely
mimics the joint size and loading of humans (w100 kg body
weight), permitting the assessment of large (>1 cm) defects in
living animals. The pony knee can also ﬁt in theMR gantry and knee
coils designed for humans, permitting serial evaluations using
clinical MRI and CT. Since the medial and lateral femorotibial joints
are noncommunicating in the equine species, carriage of viral
vectors from one compartment to another is limited47.
Our exploratory study has demonstrated a small, but statisti-
cally signiﬁcant, effect of BMP gene delivery into osteochondral
defects. The clinical signiﬁcance of the limited improvement in
subchondral bone density is unknown and would be speculative
due to our low sample size. Indeed in our current study we
demonstrated statistically signiﬁcant differences in these similar
bone parameters. Ability to detect chondral differences among our
treatments may have been limited by our low power. However,
since none of the cartilage defects were effectively healed by the
BMPs, we concluded that although delivery of BMP-2 or BMP-6 to
largeweight-bearing osteochondral defects via Ad vector and direct
injection provided evidence of support to cartilage and sub-
chondral bone regeneration, it was insufﬁcient to provide long-
term quality osteochondral repair in the pony model.
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